Literature DB >> 17116839

Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor.

Shannon Routhouska1, Anita C Gilliam, Paradi Mirmirani.   

Abstract

BACKGROUND: Hair pigmentation is regulated by several factors including the interaction of the ligand stem cell factor (SCF) with its class III receptor tyrosine kinase, c-kit. An interruption of SCF/c-kit signal transduction results in hair depigmentation. OBSERVATIONS: A 69-year-old white woman developed hair depigmentation and fine-textured hair while being treated with the phase I chemotherapeutic agent GW786034, a class III/V receptor tyrosine kinase inhibitor. Discontinuation of therapy resulted in a reversal of these hair changes.
CONCLUSIONS: Treatment with oral GW786034 resulted in reversible hair depigmentation and change in hair growth rate and texture, which were most likely due to an incomplete inhibition of SCF/c-kit signaling, although the exact mechanism is unknown. It would be intriguing to investigate topical tyrosine kinase inhibitors as a treatment for unwanted body hair.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116839     DOI: 10.1001/archderm.142.11.1477

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

Review 1.  (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.

Authors:  Paul Hamberg; Jaap Verweij; Stefan Sleijfer
Journal:  Oncologist       Date:  2010-05-28

Review 2.  Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.

Authors:  Sidney V Keisner; Sachin R Shah
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

3.  Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib.

Authors:  Hwan-Jung Yun; Young Joon Seo; Hyo Jin Lee
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

4.  Overall clinical and trichoscopic analysis performed in patients who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis - initial trial preliminary report.

Authors:  Maciej Nowacki; Katarzyna Nowacka; Iwona Głowacka; Barbara Zegarska; Wojciech Zegarski
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

5.  Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases.

Authors:  Jiayong Liu; Zhengfu Fan; Shu Li; Tian Gao; Ruifeng Xue; Chujie Bai; Lu Zhang; Zhichao Tan; Zhiwei Fang
Journal:  Ann Transl Med       Date:  2020-11

Review 6.  Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.

Authors:  Naomi B Haas; Robert G Uzzo
Journal:  Curr Treat Options Oncol       Date:  2007-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.